In China, Surveyed Nephrologists Report Significant Declines in the Use of ESAs in Stage 3, 4 and 5 Chronic Kidney Disease Non-

  In China, Surveyed Nephrologists Report Significant Declines in the Use of
     ESAs in Stage 3, 4 and 5 Chronic Kidney Disease Non-Dialysis Patient
                       Populations, Compared with 2011

After Review of Three Renal Anemia Product Profiles in Development, Expected
Use Increases with Disease Severity, According to Findings from Decision
Resources Group

PR Newswire

BURLINGTON, Mass., July 1, 2014

BURLINGTON, Mass., July 1, 2014 /PRNewswire/ --Decision Resources Group finds
that patient chart data submitted by surveyed nephrologists in China reveals
that, consistent with 2011, the percentage of patients on
erythropoiesis-stimulating agents (ESAs) significantly increases as chronic
kidney disease (CKD) worsens; however, for stage 3, stage 4 and stage 5
non-dialysis (ND), the percentage of patients on ESAs has declined
significantly compared with 2011. 

Decision Resources Group Logo.

Other key findings from the report entitled ChartTrends: Renal Anemia in
CKD-ND (China) 2014:

  oESA-treated patient demographics: Patients treated with ESAs tend to be in
    a later stage of CKD; tend to have more comorbidities and lower hemoglobin
    levels; are more likely to be on traditional Chinese medicine for the
    treatment of renal anemia; are more likely to be on iron (IV or oral),
    phosphate binders, and active Vitamin D; and are of higher economic status
    compared with ESA non-treated patients. (The report also includes patient
    share data for Shenyang Sunshine Pharmaceutical's Yi Bi Ao, Kyowa Hakko
    Kirin's ESPO, Hua Bae Pharm's Ji Main Xin and other agents.)
  oOver-reporting of IV iron use in Stage 3: While surveyed nephrologists'
    report that the percentage of CKD stage 4 patients on IV iron is
    consistent with chart audited data, respondents appear to overestimate the
    percentage of stage 3 patients who are treated with IV iron. (The report
    also includes further details on IV iron patient share, discontinuation
    rates, transferrin saturation and ferritin distributions at last measure
    and at IV iron initiation, IV iron administration location, dosing,
    switching and rationale for switching from oral to IV iron, among other
  oExpected use of products in development: New to this study, nephrologists
    reviewed product profiles of three products in late-stage development for
    renal anemia. Then, nephrologists indicated whether a particular patient
    would or would not be eligible for treatment with these products and why
    or why not they would be eligible for treatment with these products. Among
    those that would be eligible, nephrologists were asked whether a patient's
    current ESA use would change. Products covered in the report include
    FibroGen's/AstraZeneca's/Astellas's roxadustat, Akebia's AKB-6548 and
    Keryx/Japan Tobacco's Zerenex/Riona. Not surprisingly, expected use
    increases with stage of the disease.

Comments from Decision Resources Group Director Rob Dubman:

  o"It is not surprising that information from patient charts show declines
    in the use of ESAs because we have generally observed this trend in other
    markets around the globe as well."
  o"Adding product profiles to this study created some interesting findings.
    For example, this physician exercise allows manufactures to see how
    expected use differs by lab values and/or other patient demographics."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and
insights on critical issues within the healthcare industry. Clients rely on
this analysis and data to make informed decisions. Find out more at

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort


SOURCE Decision Resources Group

Press spacebar to pause and continue. Press esc to stop.